FDA Proposes Faster Path for Chewable OTC Drug Updates
Published Date: 6/5/2025
Notice
Summary
The FDA is making it easier for companies to switch certain OTC pills into chewable tablets, dissolving tablets, or films without extra paperwork. This helps drug makers update their products faster while keeping safety rules in check. If approved, these minor changes could save time and money for everyone involved.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Allow minor OTC dosage-form switches
If you make over‑the‑counter (OTC) monograph drugs, the FDA proposes allowing certain minor dosage form changes — from tablets or capsules to chewable tablets, orally disintegrating tablets, or films — without issuing a separate order to amend the OTC monograph or separately finding the new dosage form to be generally recognized as safe and effective (GRASE). This change applies only when the product conforms with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements.
Speeds updates and cuts paperwork/costs
The proposed order is intended to let drug makers update certain OTC products faster and without extra paperwork, which the FDA says could save time and money for everyone involved. If finalized, manufacturers could implement eligible dosage‑form changes more quickly than under the current separate‑order process.
Dosage changes still subject to safety rules
The FDA says the minor dosage form changes are allowed only when the products conform with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements, so safety and legal standards remain in force. That means companies cannot use this pathway unless they meet the same safety and statutory requirements described in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17498, Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The Food and Drug Administration (FDA or Agency) is extending the effective date of the notice published in the Federal Register on May 27, 2026, entitled "Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661" (91 FR 31462) (the "May 2026 Notice"), as previously extended by the notice published in the Federal Register on June 26, 2026 (91 FR 38717) (the "June 2026 Notice"), by an additional 41 days. The effective date of the May 2026 Notice, which was previously extended to September 24, 2026, is hereby further extended to November 4, 2026. This further extension is necessary to allow FDA sufficient time to consider issues raised by interested parties.
2026-17401, Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CABAZITAXEL (cabazitaxel) solution (injection), 60 milligrams (mg)/6 milliliters (mL) (10 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for Cabazitaxel (cabazitaxel) solution (injection), 60 mg/6 mL (10 mg/mL), if all other legal and regulatory requirements are met.
2026-17380, International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
The FDA is asking the public to share their thoughts on eight drugs that might get new international rules to control their use and abuse. This affects doctors, patients, and drug makers because it could change how these drugs are used medically or restricted worldwide. Comments are open until September 3, 2026, so jump in and have your say before the deadline!
Previous / Next Documents
Previous: 2025-10251, Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability
Hey makers of over-the-counter solid pills! The FDA just dropped a draft guide to help you make small changes to your products without a headache. Follow these tips to stay on track, save time, and avoid extra costs while keeping your meds safe and sound.
Next: 2025-10253, Over-the-Counter Monograph Condition B001: Single-Unit or Unit-Dose Containers for Over-the-Counter Monograph Drugs in Orally Disintegrating Tablet and Film Dosage Forms
The FDA wants to make sure certain over-the-counter medicines that dissolve in your mouth come in single-use packages. This change helps keep doses safe and easy to use, especially for kids and busy folks. If this rule passes, drug makers will need to update their packaging soon, which might cost a bit but will make medicine safer for everyone.